166 related articles for article (PubMed ID: 23072245)
41. Esophageal Crohn's disease treated successfully with adalimumab.
Kwan LY; Conklin JL; Papadakis KA
Inflamm Bowel Dis; 2007 May; 13(5):639-40. PubMed ID: 17221856
[No Abstract] [Full Text] [Related]
42. [Adalimumab vasculitis in a patient with Crohn's disease].
Muñoz Villafranca C; Izu Belloso RM; Bravo Rodriguez MT; Basterra Olabarrieta S
Gastroenterol Hepatol; 2013 Apr; 36(4):296-7. PubMed ID: 23522950
[No Abstract] [Full Text] [Related]
43. Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.
Malesci A; Angelucci E; Bonifacio C; Sociale O; Omodei P; Repici A; Balzarini L; Danese S
Inflamm Bowel Dis; 2009 Jun; 15(6):814-5. PubMed ID: 18831523
[No Abstract] [Full Text] [Related]
44. [Crohn's disease: diagnosis and treatment].
Yamamoto-Furusho JK
Rev Gastroenterol Mex; 2013 Aug; 78 Suppl 1():68-70. PubMed ID: 24041064
[No Abstract] [Full Text] [Related]
45. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK
Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
[TBL] [Abstract][Full Text] [Related]
46. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
47. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
[TBL] [Abstract][Full Text] [Related]
48. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
49. Adalimumab for cutaneous metastatic Crohn's disease.
Cury DB; Moss AC; Elias G; Nakao A
Inflamm Bowel Dis; 2010 May; 16(5):723-4. PubMed ID: 19728388
[No Abstract] [Full Text] [Related]
50. Anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?
Magro F; Coelho R; Guimarães LS; Silva M; Peixoto A; Lopes S; Macedo G
Scand J Gastroenterol; 2016; 51(4):511-2. PubMed ID: 26523855
[No Abstract] [Full Text] [Related]
51. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
52. Sjögren's syndrome associated with Crohn's disease successfully treated with adalimumab.
Tursi A
J Crohns Colitis; 2012 Mar; 6(2):263. PubMed ID: 22325185
[No Abstract] [Full Text] [Related]
53. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
54. [New therapeutic strategy for patients with Crohn's disease using of adalimumab].
Motoya S; Yamashita M; Tanaka H
Nihon Shokakibyo Gakkai Zasshi; 2012 Mar; 109(3):370-7. PubMed ID: 22398901
[No Abstract] [Full Text] [Related]
55. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
Williams CJ; Peyrin-Biroulet L; Ford AC
Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
[TBL] [Abstract][Full Text] [Related]
56. Adalimumab for a co-existing clinical condition of Crohn's disease and acrodermatitis continua of Hallopeau.
Caputo F; Parro S; Zoli G
J Crohns Colitis; 2011 Dec; 5(6):649. PubMed ID: 22115391
[No Abstract] [Full Text] [Related]
57. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease?
Tursi A
Aliment Pharmacol Ther; 2013 Apr; 37(7):752. PubMed ID: 23458532
[No Abstract] [Full Text] [Related]
58. On the probable association of adalimumab and diffuse retinopathy in a patient with Crohn's disease.
Katsanos A; Asproudis I; Katsanos K; Tsianos EV
J Crohns Colitis; 2013 Feb; 7(1):e22. PubMed ID: 22784948
[No Abstract] [Full Text] [Related]
59. [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies].
Jałocha Ł; Wojtuń S; Wojtkowiak M; Błaszak A; Dyrla P; Gil J
Pol Merkur Lekarski; 2009 May; 26(155):491-2. PubMed ID: 19606707
[TBL] [Abstract][Full Text] [Related]
60. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
